MERIDEN —Manon Cox, president and CEO of Protein Sciences Corp., is leaving the company five months after its sale to Sanofi Pasteur, the company said Tuesday.
Sanofi Pasteur confirmed Cox’s imminent departure in an email statement Tuesday.
“Sanofi Pasteur confirms that Manon Cox will leave Protein Sciences to pursue other opportunities.” the company stated. “Protein Sciences has been successfully and fully integrated into Sanofi Pasteur and, as such, there is no role of CEO for Protein Sciences. Separation has been done in compliance with Manon Cox’s existing working contract.”
Cox, who led the company through federal approval of its signature Flublok vaccine, could not be reached for comment. Daniel Adams, former Protein Sciences board chairman, also could not be reached for comment.
Cox joined Protein Sciences in 1998 and followed Adams as president and CEO in April 2012. The company was acquired in July 2017 by Sonofi for $650 million up front, and an additional $100 million if its vaccine reaches unspecified milestones under Sanofi. Cox was named transition team leader.
Protein Sciences was among the first to use genetic engineering and cell culture to manufacture its vaccine instead of the traditional method that relies on millions of chicken eggs. The company’s platform is also used to develop other vaccines to treat a variety of diseases.